Ratings Armata Pharmaceuticals, Inc.

Equities

Market Closed - Nyse Other stock markets 04:10:00 2024-05-16 pm EDT			5-day change	1st Jan Change
2.65 ^USD	0.00%		-18.71%	-18.21%

May. 07	Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q1 Revenue $966,000	MT
Mar. 21	Earnings Flash (ARMP) ARMATA PHARMACEUTICALS Reports Q4 Revenue $1.5M	MT

Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

	1st Jan change	Capi.	ESG Refinitiv
ARMATA PHARMACEUTICALS, INC.	-18.21%	95.81M	-
MODERNA, INC.	+33.37%	50.85B	B-
IQVIA HOLDINGS INC.	+1.55%	42.82B	B
LONZA GROUP AG	+49.11%	42.03B	A
CELLTRION, INC.	-4.22%	29.55B	C
ICON PUBLIC LIMITED COMPANY	+11.57%	26.11B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	19.13B	B
BIO-TECHNE CORPORATION	+7.36%	13.05B	B+
MEDPACE HOLDINGS, INC.	+28.30%	12.16B	C+
UNITED THERAPEUTICS CORPORATION	+23.80%	12.08B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality